Grail, which is looking to develop a blood test to detect early-stage cancer, has filed to go publicGrail's biggest investor is DNA machine maker Illumina, and Amazon's Jeff Bezos is also an investor.Grail, a start-up trying to develop a blood test to detect early-stage cancer, has filed for an initial public offering of stock.
The biotechnology company reported a $136.4 million loss and no revenue in the first half of 2020. The loss widened from $117.2 million one year earlier. Most of the company's losses come from research and development expenses, including the costs of developing technology and running clinical studies.
"We have never generated revenue from product sales, do not expect any near-term revenue to offset our ongoing operating expenses, and may never be profitable," the company cautioned in Wednesday's filing. Although it's unusual for information technology companies to go public pre-revenue, it's more common in the biotech space, where some young companies use IPOs to raise money to help fund the extensive research and trials necessary for medical products. Among other examples,
chrissyfarr Am I reasonable to be concerned that over detection may lead to over treatment? All kinds of data have come out suggesting that millions of men have had their private parts mangled due to overly aggressive treatment for prostate cancer. Could Grail amplify this effect?
Gotta cash in on the stock market mania while the going is good.
$SZLS Already does this. Canada is way ahead in this space.$GNWSF
these day's you can detect cancer with so called computer's but nothing beat's good old fashioned doctor's missing a diagnosis with hammer tap's to the knee
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »